ArticleIJID regions2026
Epidemiology, clinical features, and outcomes of Mpox in children and adolescents in Uganda, August 2024-January 2025.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Recent Mpox outbreaks in Uganda have primarily affected adults, but children and adolescents are at a higher risk of severe disease. We described the epidemiology, severity, and factors associated with severe Mpox among children and adolescents in Uganda during August 2024-January 2025. Methods: We conducted a cross-sectional study among polymerase chain reaction-confirmed Mpox cases in patients aged 0-17 years in eight high-burden districts. Medical records were reviewed, and Mpox severity was measured using the severity scoring system. Participants' variables were summarized using descriptive statistics and attack rates. Modified Poisson regression identified factors associated with severe disease. Results: Among 160 case-patients, males (attack rate [AR] = 2.2/100,000) and females (AR = 2.1/100,000) were equally affected. Children <5 years had the highest AR (3.7/100,000). Household (50%) and school (36%) exposures were most common. Overall, Mpox severity was 91% (adjusted prevalence ratio [aPR], 95% confidence interval: 87-96%). Care-seeking after 7 days from symptom onset was associated with higher severity (aPR: 1.1, 95% confidence interval: 1.03-1.3). Case fatality was 1.9%. Conclusions: Children, especially those younger than 5, experienced high Mpox infection, often linked to household and school exposure. Care-seeking beyond 7 days increased disease severity. Interventions promoting early detection and timely care in households and schools could reduce Mpox-related morbidity and mortality in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.